Compare Gilead Sciences, Inc. (GILD) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs McDonald's Corp — how do they compare? Gilead Sciences, Inc. trades at $135.53 (market cap $163.51B), while McDonald's Corp trades at $272.16 (market cap $188.25B). The key difference: McDonald's Corp is the larger of the two by market cap, and McDonald's Corp pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| GILD | MCD | |
|---|---|---|
Market Cap | $163.51B | $188.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $341.06 |
52-Week Low | $108.22 | $264.54 |
Enterprise Value | $178.05B | $241.96B |
Dividend Yield | 2.49% | 2.81% |
Volume | — | 2,230,036 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
McDonald's (MCD) trades at $268.94, down 1.35% on the day, with a bearish technical signal driven by moving averages. The stock shows strong fundamentals, including a 31.62% net income margin and consistent revenue growth, reaching $26.89B in 2025. Recent news highlights the company's 'McDonald's NEXT' strategy focusing on automation and menu innovation to counter competition and inflation pressures.
The outlook remains positive with a consensus price target of $326.36, implying 21% upside, supported by 59.68% analyst buy ratings. Key risks include inflationary cost pressures on franchisee margins and high long-term debt of $38.42B. Earnings momentum is mixed, with a Q2 2026 estimate of $3.33 EPS to watch.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
